RESUMEN
MT201 is a fully human monoclonal IgG1 antibody with moderate affinity for epithelial cell adhesion molecule (Ep-CAM) being clinically developed for the treatment of carcinomas. Like many other clinically validated IgG1 monoclonal antibodies, MT201 primarily acts by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, we analysed ADCC and CDC induced by MT201 and, as reference, trastuzumab against a panel of nine human breast cancer cell lines expressing distinct surface levels of Ep-CAM and human epithelial growth factor receptor type 2 antigen. Maximal cell lysis by ADCC by MT201 and trastuzumab in the presence of peripheral mononuclear cells did not significantly differ when averaged over the nine cell lines, but showed marked differences with respect to individual cell lines. The extent of cell lysis at intermediate surface target density was highly variable, suggesting a dominant influence of other susceptibility factors. Only one breast cancer cell line was eliminated via CDC, but only by MT201. Resistance to CDC appeared to correlate with high expression levels of complement resistance factors. Our present data as well as recent data on the prevalence and prognostic relevance of Ep-CAM expression in metastatic breast cancer suggest that Ep-CAM-specific monoclonal IgG1 antibodies may have a significant therapeutic potential in the treatment of breast cancer.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Citotoxicidad Celular Dependiente de Anticuerpos , Neoplasias de la Mama/tratamiento farmacológico , Moléculas de Adhesión Celular/farmacología , Activación de Complemento/efectos de los fármacos , Animales , Anticuerpos Monoclonales Humanizados , Antígenos de Neoplasias/biosíntesis , Antígenos de Neoplasias/inmunología , Moléculas de Adhesión Celular/biosíntesis , Moléculas de Adhesión Celular/inmunología , Línea Celular Tumoral , Molécula de Adhesión Celular Epitelial , Humanos , Receptor ErbB-2/biosíntesis , TrastuzumabRESUMEN
Recently we reported about a possible involvement of extrarenal systemic cytomegalovirus (CMV) infection in graft deteriorating immune processes. We now examined whether Epstein-Barr virus (EBV) may also be associated with late renal graft injury. We analyzed the expression of early antigen-, viral capsid antigen-, and a latency-associated EBV-RNA-transcript, which is not translated into protein in peripheral blood mononuclear cells of kidney transplant patients with histologically proven late acute rejection and no signs of CMV or any other infection (A), patients with stable graft function (B), and healthy probands (C). A total of 40% in group A vs. 5 and 0% in groups B and C, respectively, expressed early antigen-mRNA (P<0.05) suggesting an activation of lytic EBV infection. Response to steroid bolus therapy in group A was comparably poor with that observed in CMV-related graft injury. Our data suggest that extrarenal lytic EBV infection may also be involved in the pathogenesis of late graft injury. A controlled ganciclovir trial may prove the significance of our observation.
Asunto(s)
Infecciones por Virus de Epstein-Barr/complicaciones , Rechazo de Injerto/virología , Trasplante de Riñón , Enfermedad Aguda , Adulto , Antígenos Virales/análisis , Cápside/inmunología , Femenino , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/inmunología , Humanos , Masculino , Persona de Mediana Edad , ARN Viral/análisis , Factores de TiempoRESUMEN
The ability of the Epstein-Barr virus (EBV) to avoid lytic replication and to establish a latent infection in B-lymphocytes is fundamental for its lifelong persistence and the pathogenesis of various EBV-associated diseases. The viral immediate-early gene BZLF-1 plays a key role for the induction of lytic replication and its activity is strictly regulated on different levels of gene expression. Recently, it was demonstrated that BZLF-1 is also controlled by a posttranscriptional mechanism. Transient synthesis of a mutated competitor RNA saturated this mechanism and caused both expression of the BZLF-1 protein and the induction of lytic viral replication. Using short overlapping fragments of the competitor, it is shown that this control acts on the unspliced primary transcript. RT-PCR demonstrated unspliced BZLF-1 RNA in latently infected B-lymphocytes in the absence of BZLF-1 protein. Due to the complementarity of the gene BZLF-1 and the latency-associated gene EBNA-1 on the opposite strand of the genome, we propose an antisense-mediated mechanism. RNase protection assays demonstrated transcripts in antisense orientation to the BZLF-1 transcript during latency, which comprise a comparable constellation to other herpesviruses. A combined RNAse protection/RT-PCR assay detected the double-stranded hybrid RNA, consisting of the unspliced BZLF-1 transcript and a noncoding intron of the EBNA-1 gene. Binding of BZLF-1 transcripts is suggested to be an important backup control mechanism in addition to transcriptional regulation, stabilizing latency and preventing inappropriate lytic viral replication in vivo.
Asunto(s)
Proteínas de Unión al ADN/genética , Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/genética , ARN sin Sentido/fisiología , ARN Viral/fisiología , Transactivadores/genética , Proteínas Virales/genética , Latencia del Virus/genética , Linfocitos B , Línea Celular , Antígenos Nucleares del Virus de Epstein-Barr/genética , Herpesvirus Humano 4/fisiología , Plásmidos/genética , Empalme del ARN , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transcripción Genética , Replicación ViralRESUMEN
Infectious mononucleosis (IM) is a self-limiting, lymphoproliferative disease induced by primary infection with the Epstein-Barr virus (EBV). Infection with EBV leads in general to lifelong asymptomatic persistence of the virus. We report the case of a woman who acquired IM at the age of 15 years and then suffered from recurrent high fever, fatigue, and signs of immunologic disorder for more than 12 years until she died of liver failure. In an attempt to describe and to define the course of chronic active infection with EBV, we performed immunologic and molecular assays that demonstrated lytic replication of EBV in the B and T cells of the peripheral blood. In addition to signs of humoral and cellular immune deficiency, we detected an EBV strain with an impaired capability to immortalize B cells and a tendency to lytic replication, thus contributing to the pathogenesis of this chronic active infection.
Asunto(s)
Herpesvirus Humano 4/clasificación , Mononucleosis Infecciosa/inmunología , Mononucleosis Infecciosa/virología , Adulto , Anticuerpos Antivirales/análisis , Antígenos Virales/análisis , Enfermedad Crónica , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Resultado Fatal , Femenino , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Mononucleosis Infecciosa/diagnóstico , Fenotipo , Reacción en Cadena de la Polimerasa , Recurrencia , Especificidad de la EspecieRESUMEN
Uncontrolled replication of a virus, which is harmful to the host is also disadvantageous to the virus. Most viruses cannot compete with the various immune mechanisms and become eliminated in the course of infection. Therefore, only the time between infection and eradication remains for these viruses to proliferate. A few viruses, like the Herpesviruses or the papillomaviruses, however, have developed a sophisticated strategy for persisting lifelong, usually asymptomatically in the host, hiding from the immune system and producing infectious progeny at the same time. This strategy depends on a separation of latency and the lytic replication, either by time due to differentiation-dependent mechanisms or by spatial separation as the result of different host cell types. Both are true for the Epstein-Barr virus (EBV). B cells and epithelial cells have a pivotal role in the life cycle of the virus. The former can become latently infected and are thought to be the virus reservoir in vivo, whereas the latter were shown to be permissive for lytic replication. However, replication of EBV in vivo is controlled primarily by host immune mechanisms selecting for cells that are not permissive for viral replication as the result of a particular set of transcription factors. These factors control the activity of the regulatory immediate-early genes and, in addition, lytic and latent cycle regulatory genes negatively interfere with each other and thus link cellular and viral gene regulatory mechanisms. Disturbance of both the immune surveillance as well as viral gene regulation may result in EBV-associated disease.
Asunto(s)
Linfocitos B/virología , Herpesvirus Humano 4/fisiología , Proteínas Virales , Replicación Viral , Animales , Diferenciación Celular , Proteínas de Unión al ADN/genética , Regulación hacia Abajo , Regulación Viral de la Expresión Génica , Humanos , Procesamiento Postranscripcional del ARN , Transactivadores/genética , Transcripción GenéticaRESUMEN
The strategy of the Epstein-Barr virus to persist lifelong in the host depends on establishing a reservoir, which cannot be detected by the immune system but allows reactivation of the virus for shedding and transmission to a new host. Epithelial cells and B-cells play a major role in this viral strategy of EBV, since differentiating epithelial tissues were shown to be permissive for lytic replication in vivo, whereas the B-lymphocytes become predominantly latently infected. However, which cells are the reservoir and which the sites of lytic replication are not quite clear. With the technique of reverse transcription, PCR and immunohistochemistry, we demonstrated that the B-cells of the peripheral blood are a major site of virus production during the primary infection during infectious mononucleosis. These permissive B-cells were also detected after convalescence, however, the absence of any lytic transcripts suggested an efficient immunological control very early in the viral lytic cycle. Serological data on reactivation of EBV correlated with the detection of lytic cycle transcripts in the blood and thus demonstrated that the site of virus production during infectious mononucleosis must be different from that of the persistent state. In those cases, where the infection takes a chronic active course, control of lytic replication is insufficient, either on the level of immune surveillance or of viral gene regulation. We have demonstrated a virus strain with a lytic phenotype in an individual suffering chronic active infection. The impaired capability of this virus to immortalise B-cells correlated with an enhanced expression of the lytic switch gene BZLF-1 and down-regulation of latent regulatory genes in the early phase of infection.
Asunto(s)
Linfocitos B/metabolismo , Regulación Viral de la Expresión Génica/fisiología , Herpesvirus Humano 4/genética , Mononucleosis Infecciosa/virología , Enfermedad Crónica , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Mononucleosis Infecciosa/inmunología , Carga ViralRESUMEN
Primary infection with the Epstein-Barr virus (EBV) results in fatal infectious mononucleosis in up to 70% of males affected by the X-linked lymphoproliferative syndrome (XLP). This rare disease is often associated with diverse natural killer (NK)-, B- and T-cell deficiencies. We describe experiments testing whether the B lymphocytes of affected males play a role in the pathogenesis of XLP due to a low susceptibility to T-cell-mediated immunity. Using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry we detected in these B cells the expression of viral proteins EBNA-1, EBNA-2, EBNA-3A, EBNA-3C, LMP-1 and LMP-2A, which provide targets for cytotoxic T cells. Major histocompatibility complex (MHC) class I, MHC class II and the B7 costimulatory molecule were present on the cell surface. Accordingly, the EBV-infected B cells were lysed in 51Cr-release assays by T lymphocytes sharing MHC determinants with the targets. This MHC-restricted and specific lysis was confirmed in competition experiments using MHC-specific monoclonal antibodies (MAbs) and synthetic peptides. XLP-derived LCLs could also induce MHC class I-restricted memory and cytotoxic T lymphocytes. Thus, these XLP-derived B cells resembled normal LCIs in vitro with respect to induction of EBV-specific cytotoxic T cells (CTL), the ability to present EB viral antigens and the susceptibility to EBV-specific and MHC-restricted CTL-mediated killing. The failure of the immune system to eliminate these virus-infected B cells in XLP is clearly not caused by a B-cell-specific defect.
Asunto(s)
Linfocitos B/inmunología , Linfocitos B/virología , Infecciones por Herpesviridae/inmunología , Herpesvirus Humano 4/inmunología , Herpesvirus Humano 4/metabolismo , Mononucleosis Infecciosa/inmunología , Trastornos Linfoproliferativos/inmunología , Trastornos Linfoproliferativos/virología , Linfocitos T Citotóxicos/inmunología , Antígenos Virales/inmunología , Antígeno B7-1/biosíntesis , Línea Celular , Citotoxicidad Inmunológica , Epítopos/inmunología , Antígenos HLA-A/inmunología , Antígeno HLA-A11 , Infecciones por Herpesviridae/metabolismo , Antígenos de Histocompatibilidad Clase I/biosíntesis , Antígenos de Histocompatibilidad Clase II/biosíntesis , Humanos , Mononucleosis Infecciosa/metabolismo , Activación de Linfocitos/inmunología , Masculino , Reacción en Cadena de la Polimerasa , Transcripción Genética , Proteínas de la Matriz Viral/biosíntesis , Proteínas de la Matriz Viral/inmunologíaRESUMEN
Epstein-Barr virus (EBV) has been shown to establish latency in resting B lymphocytes of the peripheral blood. This creates a virus reservoir in contrast to lytic virus replication, which is thought to be restricted to differentiated epithelial cells in vivo. So far, the route of transmission between B cells and the production of progeny virus in the epithelial tissue has remained unclear. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry analysis of 16 patients with acute infectious mononucleosis (IM) and 25 healthy seropositive donors was performed to detect lytic replication gene products in B lymphocytes of the peripheral blood. Transcriptional activity was found in peripheral blood B lymphocytes (PBLs) for BZLF1 in 88%, BALF2 in 50%, and BcLF1 in 25% of the tested IM patients. All positive results were further confirmed in enriched B-cell populations by antigen determination using immunostaining with the APAAP technique. Furthermore, we detected transcripts for BZLF1 in 72% and for BALF2 in 16% of peripheral B lymphocytes of healthy seropositive donors. In contrast to patients with IM, no signals for BcLF1 were ever found in healthy seropositive donors. In these individuals, lytic replication of EBV is probably restricted by immunologic and gene regulatory mechanisms, whereas in the absence of immunologic control, reflected here by IM patients, the production of infectious virus becomes visible in PBLs.
Asunto(s)
Linfocitos B/virología , Portador Sano/virología , Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/fisiología , Mononucleosis Infecciosa/virología , Replicación Viral , Portador Sano/sangre , Humanos , Mononucleosis Infecciosa/sangre , Reacción en Cadena de la PolimerasaRESUMEN
In rare cases Epstein-Barr virus (EBV) leads to chronic active infection (CAEBV) which is characterized by persistant symptoms of infectious mononucleosis. Previously we described a case of persisting polyclonal B-cell lymphocytosis (PPBL) that was associated with CAEBV. Using reverse transcription and polymerase chain reaction we showed that in late passages of a spontaneous cell line, SM, latent EB viral genes such as EBNA1, EBNA2, EBNA3A/3B/ 3C, LMP1 and LMP2A were active. The master gene of the lytic cycle, BZLF1, was silent. This indicated that there was no general defect in immortalization and establishing latency by this CAEBV isolate SM. We obtained virus from the standard immortalizing strain B95-8 and the CAEBV strain SM from latently infected LCL quantified the number of virus particles by competitive PCR and demonstrated that the impaired capacity to immortalize umbilical cord blood lymphocytes was a virus strain-specific property, and was not due to an incapability to infect purified CD19+ B lymphocytes. Transcription of latency- and immortalization-associated genes such as EBNA1, EBNA2 and LMP2A was reduced, in contrast to a strongly enhanced activity of the master gene of the lytic cycle, BZLF1. A scenario for an antagonistic regulation of lytic and latent cycle genes is presented and a role for the pathogenesis of CAEBV is discussed.
Asunto(s)
Genes Virales/genética , Infecciones por Herpesviridae/genética , Herpesvirus Humano 4/patogenicidad , Mononucleosis Infecciosa/genética , Linfocitos B/virología , Línea Celular , ADN Viral/análisis , Humanos , Leucocitos Mononucleares/virología , Reacción en Cadena de la Polimerasa , Replicación ViralRESUMEN
Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare haematological disorder. It is characterized by activated and morphologically atypical B lymphocytes and polyclonal IgM production and has been associated with female sex, cigarette smoking, and HLA-DR7 expression. We report a case of PPBL with intermitting symptoms compatible with a chronic fatigue syndrome, recurrent erythema nodosum and multiforme. Serological findings suggested a chronic active Epstein-Barr virus (EBV) infection. Messenger RNA of EBV immediate early gene transactivation BZLF1 was detected in peripheral blood lymphocytes by reverse transcriptase PCR indicating a persistent replication of the virus. Over 2 years of observation we detected varying numbers of atypical lymphocytes. These cells hybridized with a probe specific for the EBV internal repeat region (BamHI W) which indicates a productive infection. Of interest, no reaction was observed with a probe specific for the latency-associated small RNAs (EBERs). The immunological phenotype of the polyclonal B cells was similar to B-cell lines immortalized by EBV in vitro, expressing a number of activation molecules (CD23, CD25, CD54) and the bcl-2 protein. In summary, our findings suggest that persistent EBV replication might be crucial in the development of lymphoproliferative disorders such as PPBL.
Asunto(s)
Linfocitos B/virología , Infecciones por Herpesviridae/complicaciones , Herpesvirus Humano 4/aislamiento & purificación , Linfocitosis/virología , Infecciones Tumorales por Virus/complicaciones , Antígenos CD/análisis , Secuencia de Bases , Enfermedad Crónica , Síndrome de Fatiga Crónica/complicaciones , Femenino , Antígeno HLA-DR7/análisis , Humanos , Persona de Mediana Edad , Datos de Secuencia Molecular , ARN Mensajero/análisisRESUMEN
The expression of EBV proteins and immunological properties were studied in the first stable cell line (SM) established from a patient presenting with persistent polyclonal B-cell lymphocytosis (PPBL). SM cells which represent a small population of EBV-positive atypical cells found in the peripheral blood of the patient express the KI-1 antigen (CD30) as well as the proto-oncogene bcl-2 product and cell surface markers of mature activated B lymphocytes. The cells harbour an EBV subtype A genome and contain EBNA2 protein. This argues against a transformation-incompetent virus as the main cause of the chronic active EBV infection observed in our patient. Latent membrane protein (LMP1) was weakly expressed and found predominantly in a perinuclear localization, a location which could lead to decreased immunogenicity in vivo. Similar to the EBV-transformed marmoset cell line B95-8, SM cells were in part productively infected as transcription of the immediate early gene BZLF1 could be shown and in some cells high levels of EBV-genome were detected by in situ hybridization with a BamH1 W-probe. Comparable to the atypical cells in the peripheral blood of the patient. EBV small RNAs were not detected with EBER-specific probes. Of interest, we noticed a markedly increased production of soluble CD21 (sCD21) antigen by SM cells as compared to LCL-type Burkitt's lymphoma cell lines. This could explain the elevated sCD21 levels observed in the serum of our PPBL patient and confirms our previous findings in patients with acute EBV infection. It also suggests a possible role of sCD21 in EBV-mediated regulation of the immune response and provides a possible explanation for the dysregulation of the humoral immune system observed in PPBl patients.
Asunto(s)
Linfocitos B/virología , Infecciones por Herpesviridae/inmunología , Herpesvirus Humano 4 , Linfocitosis/virología , Linfocitos B/inmunología , Secuencia de Bases , Southern Blotting , Western Blotting , Línea Celular , Infecciones por Herpesviridae/genética , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/inmunología , Humanos , Inmunofenotipificación , Linfocitosis/genética , Linfocitosis/inmunología , Datos de Secuencia Molecular , Proto-Oncogenes Mas , Receptores de Complemento 3d/análisis , Transcripción Genética , Replicación ViralRESUMEN
Regulation of the immediate-early gene BZLF1 is assumed to play a key role in triggering the lytic replication of Epstein-Barr virus (EBV). The expression of BZLF1 is regulated on multiple levels, including control of transcription by several positive and negative cis-acting elements as well as posttranslational modifications and protein-protein interactions. Localization of BZLF1 on one strand of the genome and the latent EBNA1 transcription unit on the complementary strand suggests a regulatory mechanism via hybridization of antisense RNA. With a plasmid encoding a defective BZLF1 RNA, which could not be translated, we were able to induce expression of endogenous BZLF1 gene product Zta and other proteins of the lytic cycle. Our data show for the first time that latent replication is stabilized by negative regulation of an immediate-early gene of the lytic cycle by a posttranscriptional mechanism. This might be a common theme of herpes simplex virus and EBV latency.
Asunto(s)
Proteínas de Unión al ADN/genética , Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/fisiología , Procesamiento Postranscripcional del ARN , Transactivadores/genética , Proteínas Virales/genética , Replicación Viral/genética , Secuencia de Bases , Línea Celular , Cartilla de ADN , Datos de Secuencia Molecular , Plásmidos , Biosíntesis de Proteínas , ARN Nuclear Heterogéneo/genética , ARN Nuclear Heterogéneo/metabolismo , TransfecciónRESUMEN
Epstein-Barr virus (EBV) replicates in a latent or a lytic way in the infected organism, depending on the type and level of differentiation of the host cell. The switch between latency and lytic replication was previously shown, for Burkitt's lymphoma cell lines, to depend on the viral BZLF1 gene product. Protein-DNA assays were used to identify the cis-acting elements that represent the link between regulating signal transduction pathways and the viral cascade of gene expression. Specific binding of proteins to several sites of the BZLF1 promoter during latency was shown. Induction of the lytic cycle by stimulation with 12-O-tetradecanoyl-phorbol 13-acetate abolished the binding of these proteins to the distal promoter (positions -227 to -551), suggesting a functional role for the down-regulation of promoter activity during latency. Computer analysis identified a multiply repeated sequence motif, HI, in this region and exonuclease III footprints confirmed that these sites act as specific protein recognition sites. Using a set of reporter plasmids we were able to demonstrate a negative regulatory effect of the HI motif in some B lymphoid cell lines, in contrast to epithelial HeLa cells. The HI silencer elements are different from other silencer elements described so far in respect of their sequence and protein-binding pattern during the activation of BZLF1.